Waters upgraded by Barclays with a new price target
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
Barclays upgraded Waters from Underweight to Equal Weight and set a new price target of $415.00 from $360.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $450.00 | Sector Perform → Sector Outperform | Scotiabank |
| 2/10/2025 | $360.00 → $415.00 | Underweight → Equal Weight | Barclays |
| 1/10/2025 | $430.00 | Mkt Perform → Outperform | Bernstein |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 10/8/2024 | $355.00 → $415.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $380.00 | Overweight | Wells Fargo |
| 8/1/2024 | $325.00 → $375.00 | Market Perform → Outperform | Leerink Partners |
| 6/3/2024 | $320.00 | Hold | Jefferies |
Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currencyInstruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regionsPharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and AsiaGAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currencyGAAP operating
News Summary: Offers increased versatility and data-driven insights with 43% greater motor stroke range (100 mm),1 expanding testing to more materials across diverse industries.Improved dynamic performance completes fatigue testing up to 30% faster than the competition,2 increasing the speed of product development and validation.Designed to simplify testing workflows, with automated controls and fewer process steps to help reduce operator errors and enable safer, more confident testing.ANAHEIM, Calif., and MILFORD, Mass., Feb. 4, 2025 /PRNewswire/ – MD&M West – Waters Corporat
News Summary: New and proprietary product enabling laboratories to analyze atmosphere-sensitive materials used to develop batteries, advanced polymers, and medicines in a standard laboratory benchtop-installed thermogravimetric analyzer (TGA).Reduces the cost and footprint of the TGA system by up to 50%i by helping eliminate the need for environment-controlled housing, or glovebox.Enables laboratories to increase throughput without sacrificing data quality and reliability.MILFORD, Mass., Jan. 22, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of TGA Smart-Seal™ Pans from its TA Instruments Division. The innovative, self-opening sample container is designed to e
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00
Barclays upgraded Waters from Underweight to Equal Weight and set a new price target of $415.00 from $360.00 previously
Bernstein upgraded Waters from Mkt Perform to Outperform and set a new price target of $430.00
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
8-K/A - WATERS CORP /DE/ (0001000697) (Filer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currencyInstruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regionsPharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and AsiaGAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currencyGAAP operating
MILFORD, Mass., Jan. 17, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2024 financial results conference call live on Wednesday, February 12th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12th, 2025, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years.
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)